Acomplia(Rimonabant) will be sold as Zimulti in U.S.

Now it is declared officially that Zimulti will be the name of weight loss pill acomplia in the U.S. market when it will be approved in United States.

Sanofi-Aventis ,developer of rimonabant has reserved the name which they will use for the diet drug for sale in United States if FDA approves it.

FDA advisory panel will air the pros and cons about rimonabant on June 13^th .The FDA advisory panel will also discuss the effectiveness and safety of new diet drug tradename Zimulti(rimonabant).

The notice published by the FDA Endocrinologic and Metabolic Drugs Advisory Committee said “as an adjunct to diet and exercise for obesity management in patients with a body mass index equal to or greater than 30, or a body mass index equal to or greater than 27 if accompanied by at least one cardiovascular risk factor.”

Acomplia is being classified as a life-style drug by the German state insurance system in Europe.The French government started a partial coverage for obese patients who have insufficiently controlled type 2 diabetes.